Neuvax is a vaccine consisting of the E75 peptide (the HER2 nonamer: 369–377) and GM-CSF as an adjuvant, and was used to vaccinate in phase I and phase II trials (i.e., stage II or stage III breast cancer patients who expressed HER2 at all levels (immunohistochemical staining 1+, 2+, 3+)). The gene discussed is ERBB2; the disease is breast carcinoma.